和记娱乐

Boehringer Ingelheim partners with Ribo to develop new treatments for people with liver diseases

Boehringer Ingelheim partners with Ribo to develop new treatments for people with liver diseases

Ribo and Qilu Announce Licensing Agreement for siRNA Therapeutic Targeting PCSK9

Ribo and Qilu Announce Licensing Agreement for siRNA Therapeutic Targeting PCSK9

Ribo is to Present the Latest Research Data on Two Investigational siRNA Drugs under Development at EASL2023

Ribo is to Present the Latest Research Data on Two Investigational siRNA Drugs under Development at EASL2023

Suzhou Ribo announces the first siRNA-based FXI targeting anti-thrombotic agent (RBD4059) to receive HREC approval for first-in-human study in Australia

Suzhou Ribo Life Science Co., Ltd. announces the first siRNA-based FXI targeting anti-thrombotic agent (RBD4059) to receive HREC approval for first-in-human study in Australia.

Ribo Announces Successful Passing EU GMP Audit.

Suzhou Ribo Life Science Co., Ltd. announced today that it has recently received the European Union Qualified Person Declaration (QPD) from the Qualified Person based on the positive results of the EU GMP audit conducted for its oligonucleotide manufacturing facilities located in Kunshan, China.